Thursday, September 8, 2016

New analysis showed dose adjustment of Gilotrif® (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer

… patients with advanced non-small cell lung cancer (NSCLC) were published today in … treat people with non-small cell lung cancer (NSCLC):
that has certain types … safe and effective in treating lung cancer with other abnormal EGFR genes … similar to those symptoms from lung cancer. Tell your doctor right away …

No comments:

Post a Comment